South Korea Preimplantation Genetic Testing Market

South Korea Preimplantation Genetic Testing Market Summary

As per Transpire Insight Analysis the South Korea Preimplantation Genetic Testing Market size is estimated at USD 20.8 billion in 2025 and is anticipated to reach USD 80.1 Million by 2033, growing at a CAGR of 8.41% from 2026 to 2033.

South Korea’s preimplantation genetic testing market kind of supports fertility clinics plus IVF laboratories by flagging chromosomal issues and inherited genetic conditions, before embryo transfer happens, you know. It basically helps clinicians narrow down which embryos might be more suitable based on the genetic findings, especially for people dealing with advanced maternal age, recurrent pregnancy loss, inherited disorders, or that repeated implantation failure situation. Over the last three to five years, the whole approach has drifted from tighter, single-purpose genetic assays toward wider sequencing driven workflows, so NGS alongside array based methods are being used more and more for PGT-A, PGT-M, and PGT-SR. Seoul Medical Center also points to NGS and array CGH as among the key approaches in today’s PGT practice.

At the same time, policy revisions have reshaped the fertility treatment economics a bit. Since 2024, South Korea has removed income limits for infertility-treatment support and then expanded IVF support. Later changes also tweaked the allowance, it moved from 25 procedures per couple to 25 procedures per childbirth, plus the copayment rate for women age 45 and older was lowered, from 50% down to 30% .

South Korea Preimplantation Genetic Testing Market Size & Forecast:

• South Korea Preimplantation Genetic Testing Market Size 2025: USD 42 Million
• Expected Market Value 2033: USD 80.1 Million
• Forecast CAGR: 8.41%
• Key Profile: CooperSurgical, Illumina Inc., Thermo Fisher Scientific, Natera Inc., Genea Biomedx, Vitrolife AB, Fulgent Genetics, Agilent Technologies, PerkinElmer, BGI Genomics, Roche Diagnostics, Bio-Rad Laboratories, Hamilton Thorne, Yikon Genomics, IGENOMIX

Key Market Insights

• In the Seoul Capital Area, clinical activity pretty much dominates, with fertility clinics clustered together, plus tertiary hospitals, IVF labs, and specialist reproductive medicine infrastructure all in one.
• NGS-based testing has gotten more attention, sort of swapping out the smaller, narrower workflows for chromosome- level and inherited-condition work, especially in more advanced IVF programs.
• For test use, PGT-A stays the main application, and it’s especially common among advanced maternal-age patients and recurrent pregnancy-loss cases where they really need chromosome-level embryo assessment.
• In 2024, government IVF support grew too, dropping the income eligibility limits and also bringing together fresh and frozen embryo treatment support.
• Support increased from 21 procedures to 25 procedures per childbirth, which helps make repeated assisted reproduction cycles more financially feasible, overall.
• Women aged 45 and above had a lower 30% copayment rate, that strengthens affordability for later-age IVF treatment and the genetic testing that comes with it.
• Fertility clinics are also starting to combine biopsy, DNA amplification, sequencing, and embryo-selection steps into one workflow, so it creates opportunities for integrated lab technology providers.
• AI-assisted embryo assessment is starting to show up as well, and in 2024 clinical research deep-learning embryo selection was able to support morphology-based IVF workflows, even if broader validation still needs to happen.
• On the regulation side, genetic testing is kept tightly controlled, because Korean law limits embryo genetic testing to specific hereditary-disease diagnostic purposes.
• And low national fertility levels sort of force a quality-focused IVF setting, so reproductive centers are more likely to improve embryo selection and treatment efficiency, not just depend on higher procedure volumes.

What are the Key Drivers, Restraints, and Opportunities in the South Korea Preimplantation Genetic Testing Market?

Driver: The most powerful growth pull is basically the expansion of public backing for infertility treatment. In 2024 South Korea removed income restrictions tied to infertility-treatment help and it also lifted IVF support by folding together fresh and frozen embryo treatment allowances, not in a small way. Then later reforms shifted the framing from 25 procedures per couple to 25 procedures per childbirth and they further cut the copayment rate for women aged 45 and above from 50% down to 30%. This policy turn reduces the financial friction around repeat IVF cycles, so it naturally opens more clinical room for embryo biopsy, plus genetic testing.

Restraint: But regulation stays the main structural limit. Korean law allows embryo genetic testing only for the diagnosis of muscular dystrophy and a few other specified hereditary diseases, so broader commercial use of some PGT tools is effectively blocked. That kind of regulatory line can slow the uptake of wider testing indications, and it may shrink the usable market size for laboratories and also for technology suppliers.

Opportunity: NGS integration looks like a solid expansion route. Already, Korean clinical guidance points to NGS and array CGH as key PGT methods, so there’s room for more scalable sequencing throughput, automated bioinformatics, and even more integrated lab platforms. On top of that, AI-assisted embryo assessment adds a complementary chance, because fertility centers are still trying to get steadier embryo-selection routines, even when cases get complicated.

What Has the Impact of Artificial Intelligence Been on the South Korea Preimplantation Genetic Testing Market?

Artificial intelligence is kinda moving embryo assessment away from mainly manual morphology review, toward more data-assisted selection, sort of. Deep-learning systems can look through time-lapse embryo images, pick up developmental signatures, and then nudge embryologists during embryo-ranking choices. A 2024 randomized clinical trial, published in Nature Medicine, compared deep-learning embryo selection with manual morphology-based selection, and it basically showed the increasing clinical push to validate AI-in-the-loop IVF routines. Meanwhile, in genetic-testing labs, digital automation can help with image quality verification, sample traceability and handling, sequencing-data interpretation, variant classification, and even workflow triage, so less of the day-to-day work turns into repetitive manual checking.

On top of that, predictive analytics can mix embryo development signals, genetic results, maternal context, plus lab measurements, to give stronger decision support. The useful point is not so much “replace embryologists,” but rather standardizing the repeated assessment steps, and helping labs cope with ballooning data volumes. AI may also help catch unusual sequencing patterns, flagging samples that need additional attention, which could make turnaround more consistent and lower the avoidable manual burden. Still, there’s a pretty big limitation right now: clinical datasets are hard to harmonize across clinics, because embryo imaging hardware, lab operating procedures, patient groups, and genetic-testing workflows are all different. So strong clinical validation and regulatory approval are still required before AI turns into a routine decision layer across fertility centers in Korea.

Key Market Trends

• Since 2024, broader IVF financial support has reduced the treatment cost barriers kind of , and also made more room for embryo-testing services that sit around it. 
• NGS has actually started to matter in clinics more, because fertility laboratories are drifting toward broader chromosome and genetic analysis instead of the older, narrower testing routines.
• Also the Government support rules shifted, not just from household income eligibility, but toward wider treatment access, so the overall patient economics changed across assisted reproduction services. 
• And later in 2024, support grew from 25 procedures per couple to 25 procedures per childbirth , which lets couples try more cycles without it feeling as tight.
• For women aged 45 and above the copayment rate went down , from 50% to 30% and that matters a lot for later age IVF patients. 
• In parallel, AI based embryo assessment has moved from “experimental” research toward clinical validation, and the randomized evidence was published in Nature Medicine during 2024, so that wasn’t just talk.
• Fertility labs are now linking embryo biopsy, DNA amplification, sequencing, bioinformatics, and reporting into one coordinated testing workflow, rather than treating each step like an isolated island. 
• Regulatory controls still keep steering what gets offered, since embryo genetic testing is still restricted to specific hereditary-disease diagnostic purposes only.
• In 2024 average maternal age landed at 33.7 years, which in turn strengthens clinical attention on chromosome related embryo assessment during IVF treatment. 
• And when you look at competition, more strategies focus on sequencing accuracy, faster turnaround time, lab automation, and partnerships with fertility centers, rather than pushing standalone testing products by themselves.

South Korea Preimplantation Genetic Testing Market Segmentation

By Test Type
PGT-A kinda centers on finding embryo chromosome number problems, and it still shows up a lot in advanced maternal-age IVF cases. PGT-M is different, it aims at known single-gene disorders in families, where disease-specific embryo testing is kinda needed. PGT-SR goes after structural chromosome issues that come from parental chromosomal rearrangements and associated reproductive complications. Then there’s Comprehensive Chromosome Screening, which kinda gives a wider chromosome-level view across the embryos, and Single Gene Disorder Testing which concentrates on inherited conditions tied to known pathogenic variants. Aneuploidy Screening checks chromosome-number abnormalities prior to embryo transfer. Embryo Biopsy Testing provides the biological sample, required for the later genetic testing work. Next-Generation Sequencing Tests support high throughput genetic analysis, also with more lab data generation. PCR-Based Tests give targeted amplification for particular genetic variants, and they fit well in certain testing workflows. Others, covers additional specialized testing approaches used only when there are specific clinical needs.

So in IVF workflows that need chromosome-level information, PGT-A and Comprehensive Chromosome Screening stay pretty strong. PGT-M and PGT-SR help families dealing with known hereditary or chromosomal risks, while Single Gene Disorder Testing is more about that targeted analysis for particular inherited conditions. Embryo Biopsy Testing is the bridge between lab embryology and molecular diagnostics, and Next-Generation Sequencing Tests back broader genomic analysis. PCR-Based Tests, even though they’re narrower, remain useful when focused amplification and variant detection are what you need most.

By Technology
Next-Generation Sequencing, gives kind of broad genetic and chromosome-level insight and has become more important in today’s PGT lab routines. PCR, meanwhile supports focused amplification, and it still works well for certain single-gene tests where you want a clean, targeted readout. FISH uses fluorescent probes for chromosome specific checks and it’s not going anywhere, because lots of labs already have the workflow in place. Array CGH allows chromosome copy-number assessment, and it also stays as an established PGT option. SNP Arrays use genetic markers to look at chromosomes and, in addition, they can bring extra genomic information along. Whole Genome Amplification is basically about enlarging the available embryo DNA first, when there’s only a small amount, so later testing can actually run. AI-Based Genetic Analysis leans on computational models to help interpret results and support embryo assessment. Digital PCR provides a very sensitive quantification of targeted nucleic acids for selected molecular uses. Microarray Technology supports parallel genomic analysis across multiple genetic markers. Others cover specialized lab technologies that still support genetic analysis in more niche settings.

NGS and Array CGH sit in key positions because modern PGT workflows need dependable chromosome and genetic assessment, even when the embryo material is limited and you can’t do much. PCR continues to be useful for targeted screening, and FISH plus Microarray Technology represent established methods that many labs keep using, especially where local experience and setup matter. Whole Genome Amplification helps downstream analysis when the biopsy sample ends up being scarce or just not enough for every step. SNP Arrays provide a marker based genomic overview, while Digital PCR supports highly targeted molecular quantification with good sensitivity. AI-Based Genetic Analysis adds an emerging digital layer rather than fully replacing laboratory testing, and clinical research is increasingly evaluating how AI assisted embryo assessment could fit into real world decision making.

By Application
IVF Procedures kind of are the central clinical setting, since PGT runs right alongside embryo creation, culture, biopsy, testing, and transfer, sort of all in one flow. Genetic Disorder Screening also matters here because embryo testing gets used when families have known hereditary disease risks, and they’re trying to be careful with what gets transferred. Fertility Preservation connects genetic evaluation with stored reproductive material, and then later IVF treatment, which feels kind of separate but it’s linked, too. Recurrent Pregnancy Loss helps guide the investigation of embryo chromosomal causes that show up with repeated pregnancy loss events. Then Advanced Maternal Age, it creates a clear clinical demand for chromosome focused embryo assessment, because age can shift the odds. Male Infertility supports selected IVF cases where male factor reproductive challenges are part of the picture, even though the lab work is similar. Embryo Selection uses the genetic findings alongside embryology assessments, and that helps shape transfer decisions in a more informed way. Donor Egg Programs also provide genetic assessment options, within donor assisted IVF workflows that are already in place. Research Applications are there as well, because PGT supports clinical studies, validation programs, and technology development, sometimes just to prove methods or improve them. Others is basically everything extra, covering additional reproductive medicine applications.

IVF Procedures stay the primary application, because PGT really needs an IVF generated embryo plus a laboratory biopsy workflow. Advanced Maternal Age and Recurrent Pregnancy Loss are important clinical indications, while Genetic Disorder Screening addresses families with documented hereditary risks. Embryo Selection ties genetic results to embryology decisions, and that ends up creating demand for integrated laboratory and data analysis systems. Fertility Preservation and Donor Egg Programs broaden things further, as stored oocytes and embryos move into assisted reproduction pathways.

By End User
Fertility Clinics , provide direct clinical management for IVF, embryo biopsy, genetic testing coordination, and embryo transfer. Hospitals , kind of combine reproductive medicine with more wide diagnostic , laboratory, and other specialist medical infrastructure. Genetic Laboratories do the molecular analysis, sequencing, and interpretation, plus the genetic reporting part. IVF Centers on the other hand operate specialized assisted-reproduction labs, including embryo culture and testing capabilities. Academic Research Institutes focus on clinical research, validation studies, and technology development. Diagnostic Laboratories deliver molecular and genomic testing services, usually linked with reproductive medicine. Specialty Clinics handle focused fertility and genetic-testing needs. Biotechnology Companies develop sequencing, molecular diagnostics, bioinformatics, and lab technologies. Then Others cover additional organizations that support reproductive genetic testing.

Fertility Clinics and IVF Centers are major end-user groups, because embryo workflows in clinic really need coordinated reproductive and lab services. Hospitals deliver that integrated setup, while Genetic Laboratories and Diagnostic Laboratories bring the specialized sequencing, PCR, interpretation, and reporting capabilities. Academic Research Institutes support validation for emerging PGT approaches, plus they test AI-assisted embryo assessment. Specialty Clinics manage the narrower fertility and genetic priorities. And Biotechnology Companies provide the sequencing platforms, the molecular tools, bioinformatics systems , and automation for the laboratory side.

By Sample Type
Blastocyst Biopsy gives genetic material from a more developed embryo, and it sort of shows up as a big sampling route in current PGT workflows. Cleavage Stage Biopsy does something else, it collects embryo cells early in development for genetic review. Polar Body Biopsy looks at the genetic material linked to the oocyte and it backs certain chosen testing strategies. Embryo Cells end up being the biological material used for DNA amplification and downstream genetic analysis. Oocytes supply reproductive material that matters for fertility preservation and selected genetic-testing routines. Sperm Samples back male-factor fertility assessment, plus related reproductive diagnostics. DNA Samples provide the molecular material for genetic analysis and variant detection. Frozen Embryos support testing and transfer steps that involve cryopreserved embryos. Others, well, covers extra biological materials that show up in specialized reproductive testing.

In practice Blastocyst Biopsy is important because modern embryo labs often do genetic sampling before embryo transfer happens. Cleavage Stage Biopsy and Polar Body Biopsy can be alternative sampling methods for specific clinical protocols. Embryo Cells, along with DNA Samples, are used for amplification, sequencing, PCR, and the usual molecular tasks. Meanwhile Oocytes and Frozen Embryos link PGT with fertility-preservation and cryopreservation programs. Sperm Samples mainly support reproductive diagnostics and male-factor assessment, not the direct PGT embryo analysis. Sample handling needs tight, controlled lab procedures , since the embryo material is limited. Also genetic-testing accuracy depends on dependable amplification, sequencing, interpretation and quality control, which is why everything has to be pretty consistent.

What are the Key Use Cases Driving the South Korea Preimplantation Genetic Testing Market?

IVF procedures are basically the main use case, since PGT sort of plugs right into embryo biopsy, then lab analysis, embryo choosing, and finally transfer. In 2024, government reforms kinda rolled out broader infertility support , including dropping income restrictions and also expanding IVF treatment coverage, which ends up strengthening the financial footing for repeated assisted reproduction cycles, not just once.

Advanced maternal age and recurrent pregnancy loss work as secondary applications that show up often. Fertility clinics typically use chromosome-focused testing for people with higher reproductive risk, while hospitals and IVF centers give more combined reproductive and genetic services together. Seoul Medical Center, in particular, calls out advanced maternal age and recurrent miscarriage among the clinical reasons for PGT.

Newer use cases are starting to show, like AI-assisted embryo assessment and more tightly integrated sequencing workflows. Deep-learning embryo selection got randomized clinical evaluation in 2024, so that opens a route toward digitally supported embryo ranking systems. Where this goes next, will depend on clinical proof, lab standardization, regulatory acceptance, and whether it can slot into existing IVF systems without too much friction.

Which Regions are Driving the South Korea Preimplantation Genetic Testing Market Growth?

Seoul still feels like the clear dominant regional market because the capital ends up having this very densest pileup of tertiary hospitals, fertility clinics , reproductive-medicine specialists, and advanced genomic labs. At CHA Fertility Center in Seoul, they’ve built long-running PGT know-how, and they work inside this bigger reproductive-health ecosystem that knits together IVF, genetic testing, counseling, and specialized lab infrastructure. And because so many big medical institutions are nearby, adoption of NGS-based testing tends to move quicker too, plus digitally assisted embryo evaluation is more easily taken up.

Gyeonggi Province is basically the second biggest regional contributor, but the layout looks different than in Seoul. It leans more on a strong hospital-research network, and also just the closeness to large IVF centers. CHA University Bundang Hospital in Gyeonggi-do runs a research institute, and it uses Illumina sequencing infrastructure. Meanwhile, Igenomix Korea is operating in Yongin, so there is a direct laboratory and technology base outside the capital. Put together, this mix of clinical scale, genomic research, and already-set lab operations makes Gyeonggi sit in a fairly stable position in national PGT revenue.

Now the fastest-growing momentum seems to be showing up across the main metropolitan areas beyond Seoul and Gyeonggi, as fertility providers keep expanding access to advanced testing and more specialized reproductive services. In Ulsan, for example, recent clinical activity includes research looking at PGT-A results by blastocyst development, which implies broader real-world involvement in embryo-genetic assessment, not just a small niche. Between 2026 and 2033, this geographic widening should open doors for laboratories, sequencing providers, and reproductive-technology companies that can deliver standardized testing with smoother sample logistics, plus real clinic support, and kind of streamlined workflows.

Who are the Key Players in the South Korea Preimplantation Genetic Testing Market and How Do They Compete?

Competition is, uh, moderately concentrated around firms that mix genetic-testing know-how with IVF lab techs. The whole thing mostly comes down to sequencing accuracy, interpretation quality, turnaround time , clinical evidence, how well the lab workflows get integrated, and the kind of access these companies have to fertility-clinic networks. Some local players, like GenomeCare, have those market-specific laboratory relationships, while bigger international operators tend to push ahead with proprietary platforms, bioinformatics, reproductive diagnostics, and basically an integrated IVF suite. GenomeCare runs PGT and NIPT services in Korea, and Igenomix has a dedicated Korean operation, under the Vitrolife Group banner.

CooperSurgical competes by leaning hard on technology differentiation, especially PGTai, it mixes NGS information with machine-learning models plus clinical outcome collections. Their platform has been verified on more than 350,000 embryos worldwide, and it aims to cut down the subjectivity that can show up in PGT-A interpretation. Illumina, in contrast, competes earlier in the chain through high-throughput sequencing platforms used for reproductive-genomics work, and it’s supported by an established Korean subsidiary and ties to major research institutions.

Vitrolife differentiates through vertical integration after bringing Igenomix into the fold. So it connects reproductive genetic testing with IVF lab products, and keeps Igenomix Korea inside its operating network. Thermo Fisher Scientific goes after customers with wide molecular-analysis capacity plus lab infrastructure, while Natera puts emphasis on specialized genetic-testing abilities. So the competitive direction really tilts toward companies that can link sequencing, bioinformatics, embryo workflows, and clinical services, instead of just selling standalone testing parts.

Company List

• CooperSurgical
  • Illumina Inc.
  • Thermo Fisher Scientific
  • Natera Inc.
  • Genea Biomedx
  • Vitrolife AB
  • Fulgent Genetics
  • Agilent Technologies
  • PerkinElmer
  • BGI Genomics
  • Roche Diagnostics
  • Bio-Rad Laboratories
  • Hamilton Thorne
  • Yikon Genomics
  • IGENOMIX

Recent Development News

"In July 2026, Cytogen announced the absorption merger of its wholly owned subsidiary GenomeCare. The transaction will integrate GenomeCare’s PGT and NIPT reproductive-genomics business with Cytogen’s precision-medicine platform, strengthening the company’s position in reproductive genetic diagnostics. Source:http://kind.krx.co.kr

"In February 2026, Cytogen reported that GenomeCare’s PGT and genetic-testing business had become a major contributor to consolidated performance after its 2024 acquisition. The development highlights the commercial value of integrating reproductive genetic diagnostics with a broader precision-medicine portfolio. Source:https://www.thebell.co.kr

"In March 2025, Izen Pharma Korea highlighted the domestic rollout of CooperSurgical’s PGTai 2.0, an AI-based PGT-A analysis platform launched in Korea in October 2024. The technology applies AI and expanded genetic analysis to support more consistent embryo assessment in Korean fertility treatment. Source:https://izenpharma.com

What Strategic Insights Define the Future of the South Korea Preimplantation Genetic Testing Market?

The South Korea Preimplantation Genetic Testing Market is structurally, kind of, moving toward integrated reproductive genomics services not just standalone embryo tests. The main underlying push will be the mixture of expanded IVF accessibility, more sophisticated sequencing, specialized fertility centers, and higher reliance on computational interpretation. At the same time the less obvious risk is regulatory concentration: Korean guidelines limit embryo genetic testing to certain hereditary-disease diagnostic uses, so broader PGT applications cannot commercialize as quickly as companies might want.

There’s also an emerging chance in AI-assisted interpretation that sits on top of NGS-based PGT routines. CooperSurgical’s PGTai platform already leverages clinical outcome information and machine learning, and across Korea, providers are increasingly set up to adopt advanced digital analysis via existing genomic laboratories. For market players, it helps to prioritize collaborations with high-volume reproductive centers, invest in locally validated datasets, and create regulatory-ready testing platforms instead of focusing mostly on lab pricing. With that route, teams can build defensible advantages through quicker interpretation, more uniform reporting, and stronger clinical evidence.

South Korea Preimplantation Genetic Testing Market Report Segmentation

By Test Type
• PGT-A
• PGT-M
• PGT-SR
• Comprehensive Chromosome Screening
• Single Gene Disorder Testing
• Aneuploidy Screening
• Embryo Biopsy Testing
• Next-Generation Sequencing Tests
• PCR-Based Tests
• Others

By Technology
• Next-Generation Sequencing
• PCR
• FISH
• Array CGH
• SNP Arrays
• Whole Genome Amplification
• AI-Based Genetic Analysis
• Digital PCR
• Microarray Technology
• Others

By Application
• IVF Procedures
• Genetic Disorder Screening
• Fertility Preservation
• Recurrent Pregnancy Loss
• Advanced Maternal Age
• Male Infertility
• Embryo Selection
• Donor Egg Programs
• Research Applications
• Others

By End User
• Fertility Clinics
• Hospitals
• Genetic Laboratories
• IVF Centers
• Academic Research Institutes
• Diagnostic Laboratories
• Specialty Clinics
• Biotechnology Companies
• Others

By Sample Type
• Blastocyst Biopsy
• Cleavage Stage Biopsy
• Polar Body Biopsy
• Embryo Cells
• Oocytes
• Sperm Samples
• DNA Samples
• Frozen Embryos
• Others